Maravai LifeSciences
MRVI
205 hedge funds and large institutions have $1.06B invested in Maravai LifeSciences in 2024 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 72 increasing their positions, 70 reducing their positions, and 43 closing their positions.
628% more call options, than puts
Call options by funds: $1.51M | Put options by funds: $208K
8.38% more ownership
Funds ownership: 102.55% → 110.93% (+8.4%)
3% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 70
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less first-time investments, than exits
New positions opened: 40 | Existing positions closed: 43
2% less funds holding
Funds holding: 210 → 205 (-5)
10% less capital invested
Capital invested by funds: $1.18B → $1.06B (-$122M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$35.9M |
| 2 |
BlackRock
New York
|
+$28.6M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$18.2M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$18M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
+$15.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
-$20.8M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
-$17.7M |
| 3 |
GL
GTCR LLC
Chicago,
Illinois
|
-$13.2M |
| 4 |
D.E. Shaw & Co
New York
|
-$9.67M |
| 5 |
Morgan Stanley
New York
|
-$7.64M |
MRVI Hedge Fund Activity: Q2 2024 in Review
205 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Maravai LifeSciences (MRVI) for Q2 2024, worth a combined $1.06B — down 10% from $1.18B a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of MRVI and 40 opened new positions — a net loss of 3 holders — while 70 trimmed existing stakes and 72 added.
The largest buyer was Jennison Associates, adding an estimated $35.9M. The largest seller was First Trust Advisors, exiting entirely with an estimated $20.8M sold.
- 205 institutional investors held Maravai LifeSciences (MRVI) as of Q2 2024, down from 210 in Q1 2024.
- Funds reported $1.06B of Maravai LifeSciences stock for Q2 2024, down 10% quarter-over-quarter.
- 40 funds opened new Maravai LifeSciences positions in Q2 2024 and 43 closed out, a net change of -3 holders.
- The largest Maravai LifeSciences buyer in Q2 2024 was Jennison Associates, an estimated $35.9M added.
- The largest Maravai LifeSciences seller in Q2 2024 was First Trust Advisors, an estimated $20.8M sold.
Based on aggregated 13F filings for Q2 2024.